Home/Pipeline/IO Safety Panel

IO Safety Panel

Multi-tissue Functional Toxicity Screening for Immuno-oncology

Pre-clinicalActive

Key Facts

Indication
Multi-tissue Functional Toxicity Screening for Immuno-oncology
Phase
Pre-clinical
Status
Active
Company

About Ncardia

Ncardia is a specialized contract research and product company built on a deep expertise in human induced pluripotent stem cell (iPSC) technology. Its core business model involves selling standardized iPSC-derived cell products (primarily cardiovascular and neural cells) and offering custom services including cell reprogramming, gene editing, differentiation, and assay development. The company serves clients across multiple therapeutic modalities—small molecules, RNA therapies, gene therapies, and biologics—aiming to de-risk and accelerate their preclinical pipelines. Ncardia operates as a private, revenue-generating platform and services company, not a therapeutic developer.

View full company profile